Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Change in Accured Expenses (2016 - 2025)

Immucell (ICCC) has disclosed Change in Accured Expenses for 16 consecutive years, with $133036.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 310.35% year-over-year to $133036.0, compared with a TTM value of -$197037.0 through Sep 2025, down 130.81%, and an annual FY2024 reading of $362606.0, up 130.97% over the prior year.
  • Change in Accured Expenses was $133036.0 for Q3 2025 at Immucell, down from $225519.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $430259.0 in Q2 2024 and bottomed at -$531203.0 in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $49175.1, with a median of $19980.0 recorded in 2024.
  • Peak annual rise in Change in Accured Expenses hit 310.35% in 2025, while the deepest fall reached 2758.67% in 2025.
  • Year by year, Change in Accured Expenses stood at $367502.0 in 2021, then dropped by 12.31% to $322265.0 in 2022, then dropped by 21.65% to $252488.0 in 2023, then crashed by 109.66% to -$24389.0 in 2024, then soared by 645.48% to $133036.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ICCC at $133036.0 in Q3 2025, $225519.0 in Q2 2025, and -$531203.0 in Q1 2025.